The outcomes of a phase II, single-arm study involving patients with microsatellite-unstable (MSI) metastatic colorectal cancer receiving treatment with nivolumab reveal high levels of effectiveness. In a heavily pretreated population, 23 patients (31% of the cohort) had an objective response, while 51 (69%) had disease

中文翻译：

---

大肠癌：Nivolumab对MSI肿瘤有效

II期单臂研究的结果涉及接受尼古鲁单抗治疗的微卫星不稳定（MSI）转移性结直肠癌患者，显示出高水平的疗效。在经过大量预处理的人群中，有23名患者（占队列的31％）有客观反应，而51名（69％）患有疾病